Novartis is set to release its third-quarter results on October 28 before the market opens. The Switzerland-based global healthcare company is currently experiencing significant momentum. This positive development is driven by strong pipeline execution, new regulatory approvals, strategically valuable licensing agreements, and consistent capital returns to shareholders.
Analysts surveyed by Refinitiv expect Novartis to report earnings per share (EPS) of USD 2.26 in its upcoming quarterly report – representing an increase of around 9.7% year over year. Revenue is projected to rise to USD 13.9 billion, marking an 8.4% increase compared to the same period last year.
We look forward to answering all of your questions about our products and how they are traded. Please don't hesitate to get in touch! Phone: 058 800 11 11, email info@leonteq.com or contact us here.